Document is current
Any future updates will be listed below
-
Authors
Zhao, Yuanyuan
Ma, Yuxiang
Zang, Aimin
Cheng, Ying
Zhang, Yiping
Wang, Xiangcai
Chen, Zhendong
Qu, Song
He, Jianbo
Chen, Chuanben
Jin, Chuan
Zhu, Dongyuan
Li, Qingshan
Liu, Xianling
Su, Wuyun
Ba, Yi
Hao, Yanrong
Chen, Junmin
Zhang, Guoping
Qu, Shenhong
Li, Yong
Feng, Weineng
Yang, Mengxiang
Liu, Baorui
Ouyang, Weiwei
Liang, Jin
Yu, Zhuang
Kang, Xiaoyan
Xue, Shilin
Yang, Guihong
Yan, Wei
Yang, Yingying
Liu, Zhi
Peng, Yufeng
Fanslow, Bill
Huang, Xian
Zhang, Li
Zhao, Hongyun
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04296994 at ClinicalTrials.govnct05171790 at ClinicalTrials.govDocuments that mention this clinical trial
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
https://doi.org/10.1186/s13045-023-01445-1
Documents that mention this clinical trial
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors
https://doi.org/10.1186/s13045-023-01445-1
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82002409, 81872449, 82073396)
Guangdong Basic and Applied Basic Research Foundation (2020A1515010020, 2018A0303130243)
- License Information
-
More Information
Article History
Received: 27 December 2022
Accepted: 26 April 2023
First Online: 8 May 2023
Declarations
:
: The study protocol and all amendments were approved by the Institutional Review Boards of all participating institutions. All participants provided written informed consent. The study was done in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.
: Not applicable.
: Li Zhang reports receiving research support from Jiangsu Hengrui Pharmaceuticals, Eli Lilly, Novartis, Roche, and Bristol-Myers Squibb. Zhi Liu, Yufeng Peng, Bill Fanslow, Xian Huang, and Wei Yan are employees of Sound Biologics. Xiaoyan Kang, Shilin Xue, Guihong Yang, and Yingying Yang are employees of Qilu Pharma Ltd. All other authors declare no potential competing interests.
